With this seemingly unrelenting bad news, what does the future hold for drug development for Alzheimer's Disease (AD)? This post provides a brief overview of the landscape of trials for AD and why there is optimism that DMDs for this devastating condition will be a case of when they will be developed not if.
The Rutuximab patent period is over, and now clinical trial experimentation of the product is available to all industry players, which is creating a huge activity of new trials with the drug. We analyze the data.
In this post we take analyze clinical trials that are operating in 5 or more countries, and we discuss in detail one in particular that has operations in 42 countries.
The Sunshine Act was enforced in 2012 to publicize institutional clinical trial payments, and reduce the amount of bribing happening in the industry. Has the industry been complying? We find out with this data analysis.
Recently we shared an analysis on the some surprising clinical trial hotspots in the US in 2017. In this post, we look at hotspots of trials already registered with the NIH for the future.
Planning ahead for a trial is important, but some teams have gone as far as registering protocols with the NIH with a 2025 start date. Here's a look at these trials of the future.
It’s no secret that conducting successful clinical trials is a difficult undertaking and that event the most talented teams fail. Which types of trials are at the highest risk of failure?
It's expected some areas of the country such as New York have more clinical trial activity, but the hotspots in this article may surprise you.
A look a the number of trials on ClinicalTrials.gov shows an exponential growth in trial activity... so what's going on and what's the implication?
We extrapolate data on 540,000 trials sites from 240,000 trial records to present to you a list of the most active trial sites in the world.